Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

28 Jun 2021

Psyched Wellness Commences Next Pre-Clinical Study on AME-1

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

25 Jun 2021

Numinus Announces Update to Escrow Release Schedule

VANCOUVER, BC, June 25, 2021 /CNW/ – Numinus Wellness Inc....

By Microdose

Press Releases

25 Jun 2021

Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

24 Jun 2021

Numinus Announces Grant of Stock Options

VANCOUVER, BC, June 24, 2021 /CNW/ – Numinus Wellness Inc....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

24 Jun 2021

Tryp Therapeutics to Present at the Psych Investor Summit

San Diego, California–(Newsfile Corp....

By Microdose

Press Releases

23 Jun 2021

Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’

TORONTO, Ontario, June 23, 2021 – Awakn Life Sciences Corp....

By Microdose

Press Releases

22 Jun 2021

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

By Microdose

Press Releases

18 Jun 2021

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

VANCOUVER, BC, June 18, 2021 /CNW/ - Numinus Wellness Inc....

By Microdose

Press Releases

17 Jun 2021

Awakn Life Sciences Corp. Announces Completion Of Reverse Takeover Transaction, Release From Escrow Of Private Placement Proceeds, And Final Approval For Listing On Neo Exchange

Vancouver, B....

By Microdose

Follow us on social

Latest News

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

WordPress Ads